Compare Gilead Sciences, Inc. (GILD) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Home Depot Inc — how do they compare? Gilead Sciences, Inc. trades at $135.88 (market cap $163.51B), while Home Depot Inc trades at $347.47 (market cap $340.46B). The key difference: Home Depot Inc is far larger — about 2.1× Gilead Sciences, Inc.'s market cap, and Home Depot Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| GILD | HD | |
|---|---|---|
Market Cap | $163.51B | $340.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $423.42 |
52-Week Low | $108.22 | $297.51 |
Enterprise Value | $178.05B | $402.01B |
Dividend Yield | 2.49% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Home Depot (HD) trades at $347.82, up 2.98% with bullish technical signals and strong institutional support. The stock shows robust fundamentals with $159.51B revenue and 8.41% net margin, though recent earnings mixed with Q3 miss but Q4 and Q1 beats. Valuation metrics include P/E of 24.25 and ROE of 128.38%, while cash flow trends indicate strategic investments. Recent news highlights institutional activity and market volatility concerns.
Outlook remains positive with analyst consensus target of $370.59 and 59% buy ratings, supported by Pro business growth and housing tailwinds. Risks include weakening big-ticket demand, margin pressure from investments, and rising mortgage rates impacting housing market sentiment. The stock presents a buying opportunity for long-term investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
